search
Back to results

The Effectiveness of a Systemic Mindfulness-based Intervention Program in a Cystic Fibrosis Clinic (Mindfulness)

Primary Purpose

Cystic Fibrosis

Status
Unknown status
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
active interventional program based on Mindfulness training
Sponsored by
Rabin Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Cystic Fibrosis focused on measuring Mindfulness, stress reduction

Eligibility Criteria

8 Years - 65 Years (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Diagnosis of CF clinically and by sweat test and/ or genetic testing and/ or nasal potential difference
  2. Treatment with one or more chronic medications or regimes;
  3. Willingness by patient or parent to sign consent form;
  4. Parents capable of complying with the program requirements including completing self-report questionnaires pre and post intervention completion.

Exclusion Criteria:

  1. Having significant developmental delay or a mental health diagnosis of psychosis;
  2. Transplant patients;
  3. Participation in other interventional studies within 2 weeks of recruitment or during the study period -

Sites / Locations

  • Schneider Children's Medical Center of IsraelRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Staff

Parents

Patients with CF

Arm Description

active interventional program based on Mindfulness training

active interventional program based on Mindfulness training

active interventional program based on Mindfulness training

Outcomes

Primary Outcome Measures

Score on the Mindful Attention Awareness Scale (MAAS)
The MAAS assesses individual differences in the frequency of mindful states over time and focuses on the presence or absence of attention to and awareness of what is occurring in the present. The MAAS includes a 15-item scale where respondents indicate how frequently they have the experience described in each statement using a 6-point Likert scale. Changes in MAAS-measured mindfulness pre-to post-intervention have been related to declines in mood disturbance and stress (reference #18).

Secondary Outcome Measures

scores on the Cystic Fibrosis Questionnaire (CFQ-R) on 12 domains
The CFQ Is a disease-specific instrument designed to measure impact on overall health, daily life, perceived well-being and symptoms, developed specifically for use in patients with a diagnosis of cystic fibrosis. The measure consists of 12 subscales: Physical, Role, Vitality, Emotional State, Social/Marginalization, Body Image, Eating Disturbance, Treatment Burden, Perception of Health, Weight, Respiratory, and Digestion. Scores range from 0-100, with higher scores indicating better health-related quality of life (HRQOL). All subscales have been shown to have adequate internal consistency and test-retest reliability and have demonstrated good convergent and discriminant validity. (reference #17)
score on the Perceived Stress Scale (PSS)
Perceived Stress Scale (reference #19): The PSS measures the degree to which individuals perceive their daily life as being stressful during the last month with a 5-point Likert scale (0 = never and 4 = very often). Total scores can range from 0 to 40. Higher scores on the PSS represent higher levels of perceived stress.
Level of depression as assessed by the Beck Depression Inventory (BDI)
The BDI is a 21-item self - report measure of depressive symptoms. Each item presents one symptom at four levels of intensity scored from 0 to 3 yielding total scores ranging from 0 to 60, with 60 being the most extreme score of depression. The BDI has been found to be a reliable and valid measure of the severity of depressive symptoms in college students and adults (21) and in adolescents (22).
Pulmonary function as assessed by spirometry: forced expiratory volume in one second (FEV1), forced expiratory flow 25-75% (FEF25-75), and forced vital capacity (FVC)
The FEV1, FEF25-75 and FVC are assessed by spirometry techniques as done in the routine procedures in the Pulmonary clinic
CF related inflammation
levels of serum C-reactive protein (CRP), sputum neutrophil %,serum interleukin 8 (IL-8) and neutrophil elastase will be assessed by routine laboratory methods in the hospital laboratory
Rate of pulmonary exacerbations
the rate of pulmonary exacerbations will be assessed by the number of days on IV antibiotics as well as pulmonary exacerbations as defined by the FUCHS criteria
Score on the Mindful Attention Awareness Scale (MAAS)
The MAAS assesses individual differences in the frequency of mindful states over time and focuses on the presence or absence of attention to and awareness of what is occurring in the present. The MAAS includes a 15-item scale where respondents indicate how frequently they have the experience described in each statement using a 6-point Likert scale. Changes in MAAS-measured mindfulness pre-to post-intervention have been related to declines in mood disturbance and stress (reference #18).
scores on the Cystic Fibrosis Questionnaire (CFQ-R) on 12 domains
The CFQ Is a disease-specific instrument designed to measure impact on overall health, daily life, perceived well-being and symptoms, developed specifically for use in patients with a diagnosis of cystic fibrosis. The measure consists of 12 subscales: Physical, Role, Vitality, Emotional State, Social/Marginalization, Body Image, Eating Disturbance, Treatment Burden, Perception of Health, Weight, Respiratory, and Digestion. Scores range from 0-100, with higher scores indicating better health-related quality of life (HRQOL). All subscales have been shown to have adequate internal consistency and test-retest reliability and have demonstrated good convergent and discriminant validity. (reference #17)
score on the Perceived Stress Scale (PSS)
Perceived Stress Scale (reference #19): The PSS measures the degree to which individuals perceive their daily life as being stressful during the last month with a 5-point Likert scale (0 = never and 4 = very often). Total scores can range from 0 to 40. Higher scores on the PSS represent higher levels of perceived stress.
Level of depression as assessed by the Beck Depression Inventory (BDI)
The BDI is a 21-item self - report measure of depressive symptoms. Each item presents one symptom at four levels of intensity scored from 0 to 3 yielding total scores ranging from 0 to 60, with 60 being the most extreme score of depression. The BDI has been found to be a reliable and valid measure of the severity of depressive symptoms in college students and adults (21) and in adolescents (22).
Pulmonary function as assessed by spirometry: forced expiratory volume in one second (FEV1), forced expiratory flow 25-75% (FEF25-75), and forced vital capacity (FVC)
spirometry technique for measuring lung function
CF related inflammation
levels of serum C-reactive protein (CRP), sputum neutrophil %,serum interleukin 8 (IL-8) and neutrophil elastase will be assessed by routine laboratory methods in the hospital laboratory
Rate of pulmonary exacerbations
the rate of pulmonary exacerbations will be assessed by the number of days on IV antibiotics as well as pulmonary exacerbations as defined by the FUCHS criteria

Full Information

First Posted
April 28, 2014
Last Updated
May 4, 2014
Sponsor
Rabin Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT02131857
Brief Title
The Effectiveness of a Systemic Mindfulness-based Intervention Program in a Cystic Fibrosis Clinic
Acronym
Mindfulness
Official Title
The Effectiveness of a Systemic Mindfulness-based Intervention Program in a Cystic Fibrosis Clinic
Study Type
Interventional

2. Study Status

Record Verification Date
May 2014
Overall Recruitment Status
Unknown status
Study Start Date
May 2014 (undefined)
Primary Completion Date
May 2015 (Anticipated)
Study Completion Date
December 2015 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Rabin Medical Center

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Hypothesis 1: Mindfulness is a feasible tool for use within a cystic fibrosis (CF) clinic Hypothesis 2: Participants in the mindfulness intervention will show an increased level of quality of life post intervention with the Mindfulness course Hypothesis 3. Levels of mindfulness: Participants in the mindfulness intervention will report increased mindfulness levels post-program completion as compared to pre-program completion Hypothesis 4. Levels of stress: Participants in the mindfulness intervention will report lower levels of stress post-program completion as compared with pre-program commencement. Hypothesis 5. Levels of residual depressive symptoms post-mindfulness intervention program: Residual symptoms of depression are a risk factor for relapse of depression. Post -program participants of mindfulness will purport fewer residual depressive symptoms compared with pre-program. Hypothesis 6. CF is associated with severe neutrophilic inflammation of the airways. As mindfulness intervention has been shown to modulate immune system it may improve physical aspects of CF including markers of inflammation and markers of lung disease (lung function tests and rate of pulmonary exacerbations) and nutritional state.
Detailed Description
The study will be an active interventional program for approximately six months in duration. All participants will initially undergo an initial assessment interview. Personnel trained and certified in mindfulness-based stress reduction (MBSR) will run mindfulness-based groups in 6-8 weekly 1 1/2 hour sessions (the staff group will comprise of 6 sessions and the parents' and patients' groups will be 8 sessions long). Participants will learn and engage in various formal and informal meditation practices during experiential learning of skills, including concentration, mindfulness of thoughts, emotions, feelings and bodily sensations, decentering, and letting go. Each group will include both practical exercises and a psycho-educational component. Daily homework, an essential aspect of the course, will include meditation practices together with exercises designed to integrate application of awareness skills into daily life. On day 0, participants will complete a battery of questionnaires as well as tests of the physical status of CF disease. This battery will be repeated at 8 weeks, and again at 6 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cystic Fibrosis
Keywords
Mindfulness, stress reduction

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
24 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Staff
Arm Type
Experimental
Arm Description
active interventional program based on Mindfulness training
Arm Title
Parents
Arm Type
Experimental
Arm Description
active interventional program based on Mindfulness training
Arm Title
Patients with CF
Arm Type
Experimental
Arm Description
active interventional program based on Mindfulness training
Intervention Type
Behavioral
Intervention Name(s)
active interventional program based on Mindfulness training
Intervention Description
active interventional program based on Mindfulness training
Primary Outcome Measure Information:
Title
Score on the Mindful Attention Awareness Scale (MAAS)
Description
The MAAS assesses individual differences in the frequency of mindful states over time and focuses on the presence or absence of attention to and awareness of what is occurring in the present. The MAAS includes a 15-item scale where respondents indicate how frequently they have the experience described in each statement using a 6-point Likert scale. Changes in MAAS-measured mindfulness pre-to post-intervention have been related to declines in mood disturbance and stress (reference #18).
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
scores on the Cystic Fibrosis Questionnaire (CFQ-R) on 12 domains
Description
The CFQ Is a disease-specific instrument designed to measure impact on overall health, daily life, perceived well-being and symptoms, developed specifically for use in patients with a diagnosis of cystic fibrosis. The measure consists of 12 subscales: Physical, Role, Vitality, Emotional State, Social/Marginalization, Body Image, Eating Disturbance, Treatment Burden, Perception of Health, Weight, Respiratory, and Digestion. Scores range from 0-100, with higher scores indicating better health-related quality of life (HRQOL). All subscales have been shown to have adequate internal consistency and test-retest reliability and have demonstrated good convergent and discriminant validity. (reference #17)
Time Frame
6 months
Title
score on the Perceived Stress Scale (PSS)
Description
Perceived Stress Scale (reference #19): The PSS measures the degree to which individuals perceive their daily life as being stressful during the last month with a 5-point Likert scale (0 = never and 4 = very often). Total scores can range from 0 to 40. Higher scores on the PSS represent higher levels of perceived stress.
Time Frame
6 months
Title
Level of depression as assessed by the Beck Depression Inventory (BDI)
Description
The BDI is a 21-item self - report measure of depressive symptoms. Each item presents one symptom at four levels of intensity scored from 0 to 3 yielding total scores ranging from 0 to 60, with 60 being the most extreme score of depression. The BDI has been found to be a reliable and valid measure of the severity of depressive symptoms in college students and adults (21) and in adolescents (22).
Time Frame
6 months
Title
Pulmonary function as assessed by spirometry: forced expiratory volume in one second (FEV1), forced expiratory flow 25-75% (FEF25-75), and forced vital capacity (FVC)
Description
The FEV1, FEF25-75 and FVC are assessed by spirometry techniques as done in the routine procedures in the Pulmonary clinic
Time Frame
6 months
Title
CF related inflammation
Description
levels of serum C-reactive protein (CRP), sputum neutrophil %,serum interleukin 8 (IL-8) and neutrophil elastase will be assessed by routine laboratory methods in the hospital laboratory
Time Frame
6 months
Title
Rate of pulmonary exacerbations
Description
the rate of pulmonary exacerbations will be assessed by the number of days on IV antibiotics as well as pulmonary exacerbations as defined by the FUCHS criteria
Time Frame
6 months
Title
Score on the Mindful Attention Awareness Scale (MAAS)
Description
The MAAS assesses individual differences in the frequency of mindful states over time and focuses on the presence or absence of attention to and awareness of what is occurring in the present. The MAAS includes a 15-item scale where respondents indicate how frequently they have the experience described in each statement using a 6-point Likert scale. Changes in MAAS-measured mindfulness pre-to post-intervention have been related to declines in mood disturbance and stress (reference #18).
Time Frame
6 months
Title
scores on the Cystic Fibrosis Questionnaire (CFQ-R) on 12 domains
Description
The CFQ Is a disease-specific instrument designed to measure impact on overall health, daily life, perceived well-being and symptoms, developed specifically for use in patients with a diagnosis of cystic fibrosis. The measure consists of 12 subscales: Physical, Role, Vitality, Emotional State, Social/Marginalization, Body Image, Eating Disturbance, Treatment Burden, Perception of Health, Weight, Respiratory, and Digestion. Scores range from 0-100, with higher scores indicating better health-related quality of life (HRQOL). All subscales have been shown to have adequate internal consistency and test-retest reliability and have demonstrated good convergent and discriminant validity. (reference #17)
Time Frame
8 weeks
Title
score on the Perceived Stress Scale (PSS)
Description
Perceived Stress Scale (reference #19): The PSS measures the degree to which individuals perceive their daily life as being stressful during the last month with a 5-point Likert scale (0 = never and 4 = very often). Total scores can range from 0 to 40. Higher scores on the PSS represent higher levels of perceived stress.
Time Frame
8 weeks
Title
Level of depression as assessed by the Beck Depression Inventory (BDI)
Description
The BDI is a 21-item self - report measure of depressive symptoms. Each item presents one symptom at four levels of intensity scored from 0 to 3 yielding total scores ranging from 0 to 60, with 60 being the most extreme score of depression. The BDI has been found to be a reliable and valid measure of the severity of depressive symptoms in college students and adults (21) and in adolescents (22).
Time Frame
8 weeks
Title
Pulmonary function as assessed by spirometry: forced expiratory volume in one second (FEV1), forced expiratory flow 25-75% (FEF25-75), and forced vital capacity (FVC)
Description
spirometry technique for measuring lung function
Time Frame
8 weeks
Title
CF related inflammation
Description
levels of serum C-reactive protein (CRP), sputum neutrophil %,serum interleukin 8 (IL-8) and neutrophil elastase will be assessed by routine laboratory methods in the hospital laboratory
Time Frame
8 weeks
Title
Rate of pulmonary exacerbations
Description
the rate of pulmonary exacerbations will be assessed by the number of days on IV antibiotics as well as pulmonary exacerbations as defined by the FUCHS criteria
Time Frame
8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
8 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Diagnosis of CF clinically and by sweat test and/ or genetic testing and/ or nasal potential difference Treatment with one or more chronic medications or regimes; Willingness by patient or parent to sign consent form; Parents capable of complying with the program requirements including completing self-report questionnaires pre and post intervention completion. Exclusion Criteria: Having significant developmental delay or a mental health diagnosis of psychosis; Transplant patients; Participation in other interventional studies within 2 weeks of recruitment or during the study period -
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Hannah Blau, MBBS
Phone
+972504057141
Email
hblau@post.tau.ac.il
First Name & Middle Initial & Last Name or Official Title & Degree
Michal Rivlin, PhD
Phone
+972522732463
Email
micheleri@clalit.org.il
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hannah Blau, MBBS
Organizational Affiliation
Rabin Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Schneider Children's Medical Center of Israel
City
Petah Tikva
ZIP/Postal Code
49202
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hannah Blau, MBBS
Phone
+972504057141
Email
hblau@post.tau.ac.il
First Name & Middle Initial & Last Name & Degree
Hannah Blau, MBBS

12. IPD Sharing Statement

Learn more about this trial

The Effectiveness of a Systemic Mindfulness-based Intervention Program in a Cystic Fibrosis Clinic

We'll reach out to this number within 24 hrs